News & Updates

Show Multimedia Only

Psychosis not uncommon in Parkinson’s disease, signals cognitive decline

14 Jan 2022 by

A significant presence of psychosis exists among patients with Parkinson’s disease (PD) in Singapore, potentially indicating a more rapid cognitive decline and progression of PD severity, reports a study.

Psychosis not uncommon in Parkinson’s disease, signals cognitive decline

14 Jan 2022

Inpatient, ED use of faecal immunochemical testing mostly incorrect: study

14 Jan 2022

A recent study has discovered inappropriate use of faecal immunochemical testing (FIT) in emergency and inpatient settings. Moreover, FIT has led to more gastroenterology consultations but is not independently associated with inpatient endoscopy.

Inpatient, ED use of faecal immunochemical testing mostly incorrect: study

14 Jan 2022

Management of allergic rhinitis – focus on Bilaxten

14 Jan 2022

Allergic rhinitis can induce two types of symptoms in patients: i) histamine-mediated symptoms such as vasodilatation, rhinorrhoea, itching and sneezing, and ii) allergic inflammation resulting from the action of eosinophils in the nasal lining. H1-antihistamine therapy is a mode of therapy that seeks to mitigate the histamine-mediated symptoms of allergic rhinitis; this therapy aims to relieve symptoms and to improve quality of life in patients.

Management of allergic rhinitis – focus on Bilaxten

14 Jan 2022

Leg muscle strength at discharge predicts rehospitalization risk in VAD implantees

14 Jan 2022 by

In patients with newly implanted ventricular assist devices (VAD), better leg extensor muscle strength (LEMS) at discharge may suggest a lower risk of rehospitalization, according to a recent Japan study.

Leg muscle strength at discharge predicts rehospitalization risk in VAD implantees

14 Jan 2022

Work-related stress not a cancer hazard

14 Jan 2022

While a commonly perceived cause of cancer, stress does not appear to contribute to an increased risk of developing cancer, a study has found.

Work-related stress not a cancer hazard

14 Jan 2022

Why does bariatric surgery confer better cardiovascular benefit to diabetics?

14 Jan 2022

Differential changes in fasting serum levels of fibroblast growth factor (FGF)-19 and FGF-21 may help account for the superior cardiovascular benefit of bariatric surgery on obese patients with type 2 diabetes mellitus vs nondiabetics, a recent study has found.

Why does bariatric surgery confer better cardiovascular benefit to diabetics?

14 Jan 2022

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

Poor outcomes in CCE patients point to need for better risk-stratification before PCI

13 Jan 2022

Patients with cholesterol crystal embolism (CCE) endure poor prognoses, highlighting the need for better identification of high-risk patients before undergoing percutaneous coronary intervention (PCI), a recent study has found.

Poor outcomes in CCE patients point to need for better risk-stratification before PCI

13 Jan 2022

Paediatric VTE: How long should anticoagulation be?

13 Jan 2022 by

A shorter duration of anticoagulant therapy of 6 weeks is as effective in preventing recurrent thrombosis as the conventional 3-month treatment course without increasing the risk of bleeding in young patients aged below 21 years old with acute provoked venous thromboembolism, according to the Kids-DOTT* trial.

Paediatric VTE: How long should anticoagulation be?

13 Jan 2022

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022 by

For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Psychosis not uncommon in Parkinson’s disease, signals cognitive decline

Psychosis not uncommon in Parkinson’s disease, signals cognitive decline

Inpatient, ED use of faecal immunochemical testing mostly incorrect: study

Inpatient, ED use of faecal immunochemical testing mostly incorrect: study

Management of allergic rhinitis – focus on Bilaxten

Management of allergic rhinitis – focus on Bilaxten

Leg muscle strength at discharge predicts rehospitalization risk in VAD implantees

Leg muscle strength at discharge predicts rehospitalization risk in VAD implantees

Work-related stress not a cancer hazard

Work-related stress not a cancer hazard

Why does bariatric surgery confer better cardiovascular benefit to diabetics?

Why does bariatric surgery confer better cardiovascular benefit to diabetics?

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

Poor outcomes in CCE patients point to need for better risk-stratification before PCI

Poor outcomes in CCE patients point to need for better risk-stratification before PCI

Paediatric VTE: How long should anticoagulation be?

Paediatric VTE: How long should anticoagulation be?

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor